Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yunjung Chae"'
Autor:
Eunji Kim, Jihyeon Han, Yunjung Chae, Hyerim Park, Saerom Kim, Seokkyun Kim, Jungmin Lee, Beom Chan Kim
Publikováno v:
Ophthalmology and Therapy. 11:639-652
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::445b465a9f741735fd9cffa58a05e165
https://doi.org/10.1007/s40123-022-00453-7
https://doi.org/10.1007/s40123-022-00453-7
Autor:
Eunji, Kim, Jihyeon, Han, Yunjung, Chae, Hyerim, Park, Saerom, Kim, Seokkyun, Kim, Jungmin, Lee, Beom Chan, Kim
Publikováno v:
Ophthalmology and therapy. 11(2)
SB11 was recently approved as a ranibizumab biosimilar by the US Food and Drug Administration (FDA) and the European Commission (EC) as a therapy for retinal vascular disorders under the brand name Byooviz™. This study was performed to assess the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfcd3ecc0de06df38914850c693934f7
https://pubmed.ncbi.nlm.nih.gov/35084693
https://pubmed.ncbi.nlm.nih.gov/35084693
Autor:
Hee-Won Seo, Minjung Kang, Sunyoung Ham, Michael A. Flores, Jinsu Song, Seung-Kyu Park, Seokkyun Kim, Hyung-chan Kim, Kyungyeol Paek, Yunjung Chae
Publikováno v:
mAbs
A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6882e9f338da0921fd6d6883569264d
https://pubmed.ncbi.nlm.nih.gov/28296619
https://pubmed.ncbi.nlm.nih.gov/28296619